Our Platform
We are decoding the role of the extracellular matrix (ECM) in health and disease to discover new drug targets, biomarkers, and novel therapeutic strategies to improve the management of fibrotic diseases and solid tumours.
Our Pipeline
The assets being developed in our discovery stage portfolio target disease-specific changes in the bioactivity and deposition of ECM proteins, with the aim of improving clinical outcomes in patients with fibrosis and solid tumours.
Our Partnerships
Agreements with Takeda Pharmaceuticals and Dompé Farmaceutici aim to create value for Engitix and our partners through the discovery of effective therapies for patients with fibrotic diseases and solid tumours.
Our People
Our ambitious and entrepreneurial team has a wealth of scientific and clinical expertise on the role of the extracellular matrix in chronic diseases and a track record of delivering molecules into the clinic.
Latest News
- Engitix appoints two additional international biotech industry leaders as Scientific Advisors 25 June 2024
- Engitix Announces Appointment of Matthew Edwards Ph.D., as SVP Discovery and Emma Huang Ph.D., as VP Data Sciences 21 May 2024
- Engitix Announces Appointment of Christopher Stevenson Ph.D., as Chief Scientific Officer 5 September 2023
Proprietary in vitro 3D tissue specific and disease specific screening
See our Partnerships
We work with pharma and biotech partners to utilise the full discovery potential of our platform
Learn more
